Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis

International Journal of Pediatric Otorhinolaryngology

Volumn 72, Issue 7, 2008, Pages 939-944

  Donne, A J ^a,b,d   Rothera, M P ^c   Homer, J J ^a,d  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Cidofovir; Respiratory papillomatosis

Indexed keywords

CIDOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; CLINICAL PROTOCOL; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED CANCER; DRUG STRUCTURE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LICENCE; MALIGNANT TRANSFORMATION; MEDLINE; NEPHROTOXICITY; OFF LABEL DRUG USE; OPTIMAL DRUG DOSE; PAPILLOMATOSIS; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY TRACT TUMOR; RETINITIS; REVIEW; TREATMENT RESPONSE; URINARY EXCRETION;

ANTIVIRAL AGENTS; CYTOSINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PAPILLOMA; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; RESPIRATORY TRACT NEOPLASMS;

EID: 44649192954     PISSN: 01655876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijporl.2008.04.003     Document Type: Review

References (40)

1. Doyle D.J., Gianoli G.J., Espinola T., and Miller R.H. Recurrent respiratory papillomatosis: juvenile versus adult forms. Laryngoscope 104 (1994) 523-527
2. Peyton S.W., and Wiatrak B. Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children?. Int. J. Pediatr. Otorhinolaryngol. 68 (2004) 413-418
3. de Villiers E.M. Papillomavirus and HPV typing. Clin. Dermatol. 15 (1997) 199-206
4. Crook T., Fisher C., Masterson P.J., and Vousden K.H. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9 (1994) 1225-1230
5. Zerfass K., Schulze A., Spitkovsky D., Friedman V., Henglein B., and Jansen-Durr P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J. Virol. 69 (1995) 6389-6399
6. Scheffner M., Huibregtse J.M., and Howley P.M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. U. S. A 91 (1994) 8797-8801
7. C.E. De, J. Descamps, S.P. De, A. Holy, (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 200, UNKNOWN (1978).
8. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., and Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U.S.A 74 (1977) 5716-5720
9. Votruba I., Bernaerts R., Sakuma T., De Clercq E., Merta A., Rosenberg I., et al. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol. Pharmacol. 32 (1987) 524-529
10. De C.E., and Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4 (2005) 928-940
11. Krejcova R., Horska K., Votruba I., and Holy A. Interaction of guanine phosphonomethoxyalkyl derivatives with GMP kinase isoenzymes. Biochem. Pharmacol. 60 (2000) 1907-1913
12. Kramata P., Votruba I., Otova B., and Holy A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol. Pharmacol. 49 (1996) 1005-1011
13. Andrei G., Snoeck R., Piette J., Delvenne P., and De C.E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol. Res. 10 (1998) 533-539
14. Xiong X., Smith J.L., and Chen M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41 (1997) 594-599
15. Lalezari J.P., Stagg R.J., Kuppermann B.D., Holland G.N., Kramer F., Ives D.V., et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. 126 (1997) 257-263
16. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. (2006)
17. Ljungman P., Deliliers G.L., Platzbecker U., Matthes-Martin S., Bacigalupo A., Einsele H., et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97 (2001) 388-392
18. Abdulkarim B., Sabri S., Deutsch E., Chagraoui H., Maggiorella L., Thierry J., et al. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21 (2002) 2334-2346
19. Santin A.D., Hermonat P.L., Ravaggi A., Chiriva-Internati M., Pecorelli S., and Parham G.P. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 83 (1998) 2346-2352
20. Li W., Thompson C.H., O'Brien C.J., McNeil E.B., Scolyer R.A., Cossart Y.E., et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int. J. Cancer 106 (2003) 553-558
21. Lindel K., Burri P., Studer H.U., Altermatt H.J., Greiner R.H., and Gruber G. Human papillomavirus status in advanced cervical cancer: predictive and prognostic significance for curative radiation treatment. Int. J. Gynecol. Cancer 15 (2005) 278-284
22. Sirianni N., Wang J., and Ferris R.L. Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol. 41 (2005) 423-428
23. Donne A.J., Hampson L., He X.T., Rothera M.P., Homer J.J., and Hampson I.N. Effects of Cidofovir on a novel cell based test system for Recurrent Respiratory Papillomatosis. Head & Neck 29 (2007) 741-750
24. Snoeck R., Wellens W., Desloovere C., Van Ranst M., Naesens L., and De Clercq E. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J. Med. Virol. 54 (1998) 219-225
25. Hennere G., Havard L., Bonan B., and Prognon P. Stability of cidofovir in extemporaneously prepared syringes. Am. J. Health Syst. Pharm. 62 (2005) 506-509
26. Bielamowicz S., Villagomez V., Stager S.V., and Wilson W.R. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 112 (2002) 696-699
27. Pransky S.M., Albright J.T., and Magit A.E. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 113 (2003) 1583-1587
28. Lee A.S., and Rosen C.A. Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis. J. Voice 18 (2004) 551-556
29. Mandell D.L., Arjmand E.M., Kay D.J., Casselbrant M.L., and Rosen C.A. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 130 (2004) 1319-1323
30. Sheahan P., Sexton S., and Russell J.D. Is intralesional cidofovir worthwhile in juvenile recurrent respiratory papillomatosis?. J. Laryngol. Otol. 120 (2006) 561-565
31. Pontes P., Avelino M., Pignatari S., and Weckx L.L. Effect of local application of cidofovir on the control of recurrences in recurrent laryngeal papillomatosis. Otolaryngol. Head Neck Surg. 135 (2006) 22-27
32. Dikkers F.G. Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir-a prospective study. Eur. Arch. Otorhinolaryngol. 263 (2006) 440-443
33. Chhetri D.K., and Shapiro N.L. A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch. Otolaryngol. Head Neck Surg. 129 (2003) 1081-1085
34. Milczuk H.A. Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: long-term results in 4 children. Otolaryngol. Head Neck Surg. 128 (2003) 788-794
35. Akst L.M., Lee W., Discolo C., Knott D., Younes A., and Koltai P.J. Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg. 129 (2003) 841-846
36. Naiman A.N., Ceruse P., Coulombeau B., and Froehlich P. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope 113 (2003) 2174-2181
37. Inglis Jr. A.F. Cidofovir and the black box warning. Ann. Otol. Rhinol. Laryngol. 114 (2005) 834-835
38. Naiman A.N., Roger G., Gagnieu M.C., Bordenave J., Mathaut S., and Ayari S. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 114 (2004) 1151-1156
39. Wemer R.D., Lee J.H., Hoffman H.T., Robinson R.A., and Smith R.J. Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 114 (2005) 836-839
40. British National Formulary (2006), BMJ Publishing group Ltd.